Ligand Pharmaceuticals (LGND) Set to Post Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Ligand Pharmaceuticals to announce earnings of $2.33 per share and revenue of $77.00 million for the quarter. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $1.97 by $0.40. Ligand Pharmaceuticals had a return on equity of 20.06% and a net margin of 67.88%. The firm had revenue of $63.69 million during the quarter, compared to analysts’ expectations of $61.30 million. The company’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.60 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $5.25 EPS for the current fiscal year and $8.35 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded up $0.41 during mid-day trading on Tuesday, reaching $308.71. 3,032 shares of the company’s stock were exchanged, compared to its average volume of 266,953. The firm has a 50-day moving average price of $294.13 and a two-hundred day moving average price of $250.02. Ligand Pharmaceuticals has a 52 week low of $175.89 and a 52 week high of $326.63. The firm has a market capitalization of $6.16 billion, a price-to-earnings ratio of 32.98, a price-to-earnings-growth ratio of 2.43 and a beta of 1.14. The company has a debt-to-equity ratio of 1.16, a current ratio of 31.18 and a quick ratio of 30.96.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on LGND shares. Oppenheimer restated an “outperform” rating and set a $326.00 price target (up from $285.00) on shares of Ligand Pharmaceuticals in a research report on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $358.00 target price on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Weiss Ratings upgraded shares of Ligand Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 21st. Stifel Nicolaus upped their target price on shares of Ligand Pharmaceuticals from $255.00 to $332.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Bank of America increased their price objective on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Ten analysts have rated the stock with a Buy rating. According to data from MarketBeat, Ligand Pharmaceuticals has a consensus rating of “Buy” and an average price target of $337.89.

Insider Buying and Selling

In other Ligand Pharmaceuticals news, Director Martine Zimmermann sold 1,200 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $285.00, for a total value of $342,000.00. Following the completion of the sale, the director owned 3,897 shares of the company’s stock, valued at $1,110,645. This trade represents a 23.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Octavio Espinoza sold 31,641 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $292.06, for a total value of $9,241,070.46. Following the transaction, the chief financial officer owned 27,696 shares of the company’s stock, valued at $8,088,893.76. This trade represents a 53.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 54,979 shares of company stock worth $16,068,898. Insiders own 5.60% of the company’s stock.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products.

The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients.